Mural Oncology Plc (MURA) Stock Price, Quote & News

Latest News on MURA

Apr 15, 2025, 8:00 AM EDT - 5 days ago

Mural Oncology Announces Plans to Explore Strategic Alternatives

Mar 25, 2025, 9:28 AM EDT - 26 days ago

Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges

Mar 25, 2025, 6:30 AM EDT - 26 days ago

Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer

Mar 11, 2025, 4:01 PM EDT - 5 weeks ago

Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones

Feb 18, 2025, 7:00 AM EST - 2 months ago

Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference

Jan 9, 2025, 4:00 PM EST - 3 months ago

Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts

Dec 3, 2024, 4:15 PM EST - 4 months ago

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 20, 2024, 4:15 PM EST - 5 months ago

Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer

Nov 11, 2024, 7:00 AM EST - 5 months ago

Mural Oncology to Participate in Two Upcoming Investor Conferences

Nov 7, 2024, 4:15 PM EST - 5 months ago

Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 7, 2024, 7:00 AM EDT - 6 months ago

Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Sep 23, 2024, 7:00 AM EDT - 7 months ago

Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi

Sep 10, 2024, 7:00 AM EDT - 7 months ago

Mural Oncology to Host First Virtual Investor Day on September 26, 2024

Aug 27, 2024, 7:00 AM EDT - 8 months ago

Mural Oncology to Present at Two Upcoming Investor Conferences

Aug 13, 2024, 7:15 AM EDT - 8 months ago

Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress

Jul 31, 2024, 7:00 AM EDT - 9 months ago

Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors

Jun 5, 2024, 4:15 PM EDT - 11 months ago

Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference

May 14, 2024, 7:00 AM EDT - 1 year ago

Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update

Apr 24, 2024, 4:00 PM EDT - 1 year ago

Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 9, 2024, 4:00 PM EDT - 1 year ago

Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting

Mar 26, 2024, 7:00 AM EDT - 1 year ago

Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update

Mar 5, 2024, 4:35 PM EST - 1 year ago

Mural Oncology Announces Upcoming Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 3, 2024, 11:53 PM EST - 1 year ago

Recent Spin Mural Oncology At An Attractive Discount To Cash And Portfolio Value

Feb 27, 2024, 7:00 AM EST - 1 year ago

Market Cap	46.52M
Revenue (ttm)	0.00
Net Income (ttm)	-128.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	5,765,000
Avg Vol	5,764,482
Day's Range	N/A - N/A
Shares Out	17.23M
Stochastic %K	77%
Beta	5.28
Analysts	Sell
Price Target	$7.67